Decera Clinical Education Oncology Podcast

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of immunotherapy for the treatment of patients with endometrial cancer. Presenters: Ana Oaknin, MD, PhD Head of Gynecologic Tumors Unit Medical Oncology Department Vall d´Hebron University Hospital Barcelona, Spain  Mansoor Raza Mirza, MD Chief Oncologist Department of Oncology,...

In this episode, Isabelle Ray Coquard, MD, PhD and Bradley J. Monk, MD, FACS, FACOG, discuss current first-line maintenance therapy options for patients with advanced ovarian cancer.  Presenters: Prof Isabelle Ray Coquard Professor of Department of Medical Oncology Clinical Science Institute of the Léon Bérard Center Lyon, France Bradley J. Monk MD, FACS, FACOG Professor Division of Gynecologic On...

In this episode, David Marks, MD, PhD, and Stéphane de Botton, MD, answer questions from clinicians on management pearls for patients with acute leukemias. Topics include: MRD in the management of ALL Therapy choice for older patients with AML Optimal use of inotuzumab ozogamicin and blinatumomab for ALL Use of CAR T-cell therapy for acute leukemias Content based on an online CME program supported...

Listen to Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing for your patients with advanced ovarian cancer. In this episode, Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing in the management of patients with advanced ovarian cancer. Topics include: Subtypes of ovarian c...

In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including: Local therapy in the context of MBC Choice of therapy after progression on available standards of care Choice of trastuzumab deruxtecan and tucatinib based on patient pre...

In this episode, an expert medical oncology panel led by Elizabeth R. Plimack, MD, MS, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses clinical pearls for the management of patients with metastatic renal cell carcinoma (RCC). Topics include: Treating beyond progression with immunotherapy Management of patients with less common histologic subtypes of RCC Potential biomarkers for RCC A...

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer questions focused on the optimizing BTK inhibitor therapy for previously untreated patients with CLL considering presentation characteristics and drug pharmacology. Presenters: Jeff P. Sharman, MD, Program Director Medical Director Hematology Research US Oncology Research Eugene, Oregon Danielle M. Brande...

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including: •           The impact of COVID-19 on CLL treatment decisions •           The use of anti-CD20 antibodies in combination with BTK inhibitors •           Considerations when r...

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including: Optimal testing for RET fusions DNA NGS vs RNA NGS Molecular testing workflows Using new selective RET inhibitors to treat patients with RET fusion–pos...

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including: Rechallenging patients with venetoclax and BTK inhibitors  Mechanism by which BTK inhibitors may reduce infusion reactions Risk of secondary malignancies with BTK inhibition...

In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including: Optimal use of approved CAR T-cell therapies for lymphoma and ALL Investigational CAR T-cell therapies for multiple myeloma Managing CAR T-cell therapy–related toxicities Presenters:...

In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include: •           Treatment sequencing with IO and TKI therapies •           Optimizing dose for patients with preexisting t...

In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and  Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including: • Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial  • Selecting therapy for a patient with lenalidomide-...

In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this setting, including optimizing treatment choices and sequencing of treatments, MRD testing in myeloma, promising BCMA-targeted agents, the promise and value of CAR T-cell therapy in myeloma, and more. Prese...

In this episode, Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for the first-line treatment of patients with metastatic renal cell carcinoma (RCC). Topics include: Choice of first-line therapy Combinations of targeted agents and immunotherapy Combinations of immune checkpoint inhibitors Active surveillance and monitoring Cytoreductive n...

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include: ASPEN: Zanubrutinib vs ibrutinib in WM OASIS: Ibrutinib...

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on MET  exon 14 testing and selecting MET-targeted therapies for patients with advanced NSCLC with topics including: Incorporating MET  exon 14 testing into standard of care Comparison of RNA-based and DNA-based NGS platforms Availability of RNA-based NGS testing around the world Usin...

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in  MET ex14 mutation–positive NSCLC with topics including: Whether testing for MET   exon 14 status should be standard of care Parallel vs sequential testing by DNA-based vs RNA-based NGS Co-occurring driver mutations in patients wit...

In this episode, Anna F. Farago, MD, PhD, and Taofeek K. Owonikoko, MD, PhD, answer questions  focused on the topic of current and evolving use of immunotherapy in patients with advanced small-cell lung cancer with topics including: Selecting between atezolizumab and durvalumab in the frontline setting Integration of lurbinectedin, a novel anticancer drug that was recently approved for the treatme...

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include: ASCEND: acalabrutinib vs idelalisib plus rituximab or BR ACE-CL-001: acalabrutinib long-term efficacy CLL14: Venetoclax p...

In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including: FLT3 inhibitors crenolanib and quizartinib Anti-CD47 antibody magrolimab IMGN632, a CD123 antibody–drug conjugate Anti-CD70 antibody cusatuzumab APR-246, targeting the TP53 mutation Content is part of...

In this episode, George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer questions about NTRK fusion testing and TRK inhibitor therapy for patients with advanced solid tumors, with topics including: Best practices in testing for NTRK fusions in solid tumors Optimal use of approved TRK inhibitors Key adverse events with TRK inhibitors and management strategies Emerging next-gener...

In this episode, Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer questions focused on the optimal selection and management of tyrosine kinase inhibitor (TKI) therapy in patients with CML, with topics including: Frontline Management of Chronic-Phase CML Selection of TKI Based on Goal of Treatment-Free Remission Changing TKIs due to Intolerance: Sec...

In this episode, an expert medical oncology panel led by John L. Marshall, MD, with Jamie E. Chaft, MD, and Scot Niglio, MD, provides a brief overview on the revolutionary changes brought by immuno-oncology to the management of gastrointestinal, thoracic, and genitourinary cancers. Then, the panel answers clinician questions on important topics such as: Selecting immuno-oncology vs targeted therap...

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on biomarker testing and selecting targeted therapy for patients with advanced non-small-cell lung cancer with topics including: How to approach discordant results with liquid vs tissue biopsies Repeating NGS testing at progression Selecting urgent treatment when molecular results are not yet availab...